vTv Therapeutics Inc. VTVT

Company Overview

vTv Therapeutics Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on the discovery and development of orally administered small-molecule therapies for metabolic and inflammatory diseases. The company operates primarily within the biotechnology and pharmaceutical industries, with research efforts historically centered on diabetes, obesity, liver disease, and central nervous system disorders. Its core value proposition has been the development of orally delivered therapeutics intended to improve patient compliance and expand treatment accessibility compared with injectable alternatives.

The company’s principal development programs have included cadisegliatin (formerly TTP399), a liver-selective glucokinase activator for type 1 diabetes, and earlier-stage inflammatory and metabolic disease candidates. vTv Therapeutics traces its origins to TransTech Pharma, founded in the late 1990s, before later rebranding as vTv Therapeutics and becoming publicly traded on Nasdaq under the ticker VTVT. The company has historically positioned itself around proprietary drug discovery technologies and structure-based chemistry capabilities intended to accelerate small-molecule development.